FLEX PHARMA receives FDA application approval for NDA217379
FLEX PHARMA, LLC has received application approval (AP) for NDA217379 from the FDA, with a standard review priority. This approval pertains to a product targeting a rare neurological condition, an area characterized by limited competition and significant unmet medical needs.